rFVII for Pediatric Acute Intracranial Hemorrhage To the Editor: A recent interesting phase IIB randomized, double-blind, placebo-controlled, dose-ranging “proof-of-concept” trial on recombinant activated factor VII (rFVIIa) for acute intracranial hemorrhage in adult patients has been reported.1 A lacking of similar experience in the pediatric population is noted. rFVIIa has been anecdotally re...

The hemostatic properties of recombinant activated factor VII (rFVIIa) are established in patients with inherited or acquired hemophilia with inhibitors and in patients with congenital factor VII deficiencies. Emerging clinical evidence suggests that there may be a wider role for rFVIIa in the management of hemorrhage associated with traumatic injury/accident and severe bleeding associated with...

A review of the recent randomized control trial evidence of the use of recombinant factor VIIa (rFVIIa) in massive bleeding. rFVIIa is a recombinant genetically engineered clotting factor that has been used for the management of haemophilia patients with inhibitors. There has been increasing use in patients with massive bleeding, even when there is no underlying coagulation disorder present. In...

Recombinant activated factor VII (rFVIIa) (NovoSeven) is a novel hemostatic agent originally developed to treat bleeding episodes in hemophilic patients with inhibitors against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities. Based on a literature search in...

SEVERAL investigators have reported the astonishing effect of recombinant activated factor VII (rFVIIa) in trauma patients with diffuse bleeding. Currently, rFVIIa is approved for the treatment of patients with hemophilia with inhibitors to factors VIII and IX. Conditions with increased thromboembolic risk, including trauma, extensive tissue damage, sepsis, arteriosclerosis, and disseminated in...

BACKGROUND Refractory blood loss is a common problem in surgeries for acute type A aortic dissections. Significant evidence has supported the benefit of using recombinant activated factor VII (rFVIIa) to control of intractable bleeding in patients after cardiac surgery. In this prospective clinical study, we present a novel method to achieve intraoperative hemostasis by using a combination of p...

AIMS To review the pharmacokinetics of rFVIIa in various patient populations, and to discuss the differences observed between groups. METHODS Based on a registry of Novo Nordisk studies, 14 studies evaluating rFVIIa pharmacokinetics following single and multiple bolus administration in healthy volunteers, adult and paediatric patients with congenital haemophilia and inhibitors, patients under...

There are limited data on the relationship between the administered dose of recombinant factor seven (rFVIIa) and the development of adverse clinical outcomes after congenital heart surgery. This single institution case series reports on dosing, adverse events, and blood product usage after the administration of rFVIIa in the congenital heart surgery patient population. A retrospective review i...

Introduction Diffuse alveolar hemorrhage (DAH) is a serious pulmonary complication seen in patients with autoimmune disorders and patients treated with chemotherapy or after hematopoietic stem cell transplantation. The clinical management of DAH is complex and the condition has a high mortality rate. Tissue factor is expressed in the lung alveoli during inflammation and therefore pulmonary admi...

As described in detail in other chapters of this volume, conditions with excessive bleeding, as are seen with uterine rupture, placenta accreta, abruption and uterine atony, often require intensive resuscitation with blood components and coagulation factors. In such circumstances, blood transfusion may be life-saving, but on occasion involves exposing the patient to additional risks. Over the y...